Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

MLA

Deborah Morosini, et al. “Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.” Case Reports in Oncology, vol. 7, no. 2, July 2014, pp. 503–08. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d1f9a1ff6ba5586d620aa50b9c824fab&authtype=sso&custid=ns315887.

APA

Deborah Morosini, Doron Lipson, Kai Wang, Mayur Patel, Siraj M. Ali, Phil Stephens, Jeffrey S. Ross, Salil Soman, Deepa Dutta, Norma Alonzo Palma, Jamie O’Connor, Gary A. Palmer, Nicholas Koutrelakos, & Vincent A. Miller. (2014). Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. Case Reports in Oncology, 7(2), 503–508.

Chicago

Deborah Morosini, Doron Lipson, Kai Wang, Mayur Patel, Siraj M. Ali, Phil Stephens, Jeffrey S. Ross, et al. 2014. “Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.” Case Reports in Oncology 7 (2): 503–8. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d1f9a1ff6ba5586d620aa50b9c824fab&authtype=sso&custid=ns315887.